Current Scenario In The AMR Industry

I want to discuss some key takeaways from the AMR conference held a few days ago in Basel. It was a good opportunity to be a part of it which also consisted of representatives from the US Senate, the Japanese Ministry of Health, the German National Association of Statutory Health Insurance Funds, the Public Health Agency of Canada, WHO, the European Medicines Agency, the European Commission, and several NGOs specializing in AMR.

Some of the interesting points are:

Small and Medium-Sized Companies

These companies are responsible for 80% of the novel antimicrobial pipeline, a counterintuitive figure as that was expected Big Pharma to be taking the grunt of the effort.

A survey among those SMEs showed that 3/4 of these companies are meeting their development goals, whereas, for the majority, their financial runway is less than one year.

Investment in AMR Activities

Within AMR activities, 10% of the investments are made in diagnostics, with 90% dedicated to identifying new antibiotics and other chemical agents.

European Commission

Little VC money is invested in this area, as it is considered too risky. But the European Commission is one of the important supporters of developing new antibiotics. They also prepared a report studying…